

**Primary endpoint:** Mean PASI reduction at Week 24; percentage of patients achieving PASI ≤1 and ≤3 at Week 24; percentage of patients achieving PASI90 and PASI100 at Week 24; adverse events

**Secondary measurements:** Patient clinical characteristics; mean reduction in BSA, PGA, and DLQI; drug survival at Week 24; identification of variables that might affect treatment response

**Eligibility:** Moderate-to-severe plaque psoriasis; age >18 years; prior treatment in clinic; prior treatment with ≥1 dose of tildrakizumab


**TRIAL DESIGN**

Retrospective, multicenter, observational study by the Spanish Psoriasis Group



**Tildrakizumab**  
**100 mg** (Dose augmentation of up to 200 mg in obese patients)  
 At 0 and 4 weeks, followed by every 12 weeks

Baseline patient characteristics (%)	N = 190
Women	45.8
Mean, years	51.45
Proportion of patients with prior biological therapy	79.8
Proportion of patients with comorbid psoriatic arthritis	17.3
	N = 154
Mean time since psoriasis diagnosis, years	19.81




**EFFICACY (Primary endpoints)**



**Proportion of patients (%)**



**EFFICACY (Secondary endpoints)**



**At W24, the assessed variables showed no significant association with efficacy of tildrakizumab**

Sex, BMI, history of psoriatic arthritis, PASI at baseline, length of psoriatic disease, and prior exposure to biological treatment did not influence the odds of achieving a PASI90, PASI100, or a PASI ≤1 response.

**Mean drug survival was 25.39 weeks, with an overall drug survival of 89.5% at W24.**

**SAFETY**

Patients with AEs:

**5.9%**

- 4 pts Infection
- 1 pt Weight loss
- 1 pt Anxiety
- 1 pt Injection site reaction
- 1 pt Migraine
- 1 pt Arthritis
- 1 pt Discontinuation (haemorrhagic ictus)
- 1 pt Death (unrelated)

**Tildrakizumab was demonstrated to be effective and safe at Week 24 in bio-experienced patients with moderate-to-severe plaque psoriasis in a real-world clinical setting in Spain.**

**Abbreviations:** AE, adverse event; BSA, body surface area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area Severity Index; PGA, Physician Global Assessment; W, week; pt, patient.

Berenguer-Ruiz S, et al. *J Eur Acad Dermatol Venereol.* 2023. Online ahead of print. DOI: 10.1111/jdv.19468